Glycopyrrolate and Renal cell carcinoma - a phase IV clinical study of FDA data

Summary:

Renal cell carcinoma is reported only by a few people who take Glycopyrrolate.

The phase IV clinical study analyzes which people take Glycopyrrolate and have Renal cell carcinoma. It is created by eHealthMe based on reports of 3,707 people who have side effects while taking Glycopyrrolate from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 18, 2023

3,707 people reported to have side effects when taking Glycopyrrolate.
Among them, 3 people (0.08%) have Renal cell carcinoma.

What is Glycopyrrolate?

Glycopyrrolate has active ingredients of glycopyrrolate. It is often used in hyperhidrosis. eHealthMe is studying from 3,777 Glycopyrrolate users for its effectiveness, alternative drugs and more.

What is Renal cell carcinoma?

Renal cell carcinoma (a kidney cancer) is found to be associated with 1,763 drugs and 1,174 conditions by eHealthMe.

Number of Glycopyrrolate and Renal cell carcinoma reports submitted per year:

Could Glycopyrrolate cause Renal cell carcinoma?

Gender of people who have Renal cell carcinoma when taking Glycopyrrolate *:

female: 33.33 %
male: 66.67 %

Age of people who have Renal cell carcinoma when taking Glycopyrrolate *:

Common drugs people take besides Glycopyrrolate *:

Common side effects people have besides Renal cell carcinoma *:

White Blood Cell Count Increased: 3 people, 100.00%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 3 people, 100.00%
Fatigue (feeling of tiredness): 3 people, 100.00%
Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 100.00%
Gastritis (inflammation of stomach): 3 people, 100.00%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 3 people, 100.00%
Headache (pain in head): 3 people, 100.00%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 100.00%
Insomnia (sleeplessness): 3 people, 100.00%
Intestinal Obstruction: 3 people, 100.00%

Common conditions people have *:

Neoplasm Malignant (cancer tumour): 3 people, 100.00%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Glycopyrrolate and have Renal cell carcinoma?

Check whether Renal cell carcinoma is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

D'souza S, Gowler V, "Glycopyrrolate‐induced respiratory arrest: an unusual side effect", Acta Anaesthesiologica Scandinavica, 2015 Mar .

Related studies

How severe was Renal cell carcinoma and when was it recovered:

Renal cell carcinoma in Glycopyrrolate

Expand to all the drugs that have ingredients of glycopyrrolate:

Renal cell carcinoma and drugs with ingredients of glycopyrrolate

Alternative drugs to, pros and cons of Glycopyrrolate:

Glycopyrrolate (3,777 reports)

Common Glycopyrrolate side effects:

Browse all side effects of Glycopyrrolate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Renal cell carcinoma treatments and more:

Renal cell carcinoma (121,046 reports)

COVID vaccines that are related to Renal cell carcinoma:

Common drugs associated with Renal cell carcinoma:

How the study uses the data?

The study uses data from the FDA. It is based on glycopyrrolate (the active ingredients of Glycopyrrolate) and Glycopyrrolate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.